Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, PSM 62% Improvement Relative Risk Mortality, MV 68% ICU admission, PSM -9% ICU admission, MV 32% Hospitalization, MV 22% c19early.org/mf Bramante et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 9,555 patients in the USA (March - December 2020) Lower mortality with metformin (p=0.029) Bramante et al., J. Medical Virology, doi:10.1002/jmv.26873 Favors metformin Favors control
Outpatient metformin use is associated with reduced severity of COVID‐19 disease in adults with overweight or obesity
Bramante et al., Journal of Medical Virology, doi:10.1002/jmv.26873
Bramante et al., Outpatient metformin use is associated with reduced severity of COVID‐19 disease in adults with overweight or.., Journal of Medical Virology, doi:10.1002/jmv.26873
Mar 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 17,396 PCR+ patients in the USA, showing lower mortality with metformin use.
risk of death, 62.0% lower, OR 0.38, p = 0.03, treatment 342, control 342, propensity score matching, RR approximated with OR.
risk of death, 68.0% lower, OR 0.32, p = 0.003, treatment 676, control 8,879, adjusted per study, multivariable, RR approximated with OR.
risk of ICU admission, 9.0% higher, OR 1.09, p = 0.78, treatment 342, control 342, propensity score matching, RR approximated with OR.
risk of ICU admission, 32.0% lower, OR 0.68, p = 0.06, treatment 676, control 8,879, adjusted per study, multivariable, RR approximated with OR.
risk of hospitalization, 22.0% lower, OR 0.78, p = 0.10, treatment 676, control 8,879, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bramante et al., 23 Mar 2021, retrospective, USA, peer-reviewed, 18 authors, study period 4 March, 2020 - 4 December, 2020.
Contact: bramante@umn.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: | Revised: 8 February 2021 | Accepted: 10 February 2021 DOI: 10.1002/jmv.26873 RESEARCH ARTICLE Outpatient metformin use is associated with reduced severity of COVID‐19 disease in adults with overweight or obesity Carolyn T. Bramante MD, MPH1 | John Buse MD, PhD2 | Leonardo Tamaritz MD3 | Ana Palacio MD, MPH3 | Ken Cohen MD4 | Deneen Vojta MD4 | David Liebovitz MD5 | Nia Mitchell MD, MPH6 | Jacinda Nicklas MD, MPH7 | Ildiko Lingvay MD, MPH, MSCS8,9 | Jeanne M. Clark MD, MPH10 | Louis J. Aronne MD11 | Erik Anderson MD, MPH12 1 | Michael Usher MD, PhD | Ryan Demmer PhD, MPH Genevieve B. Melton MD, PhD14 | Nicholas Ingraham MD15 Christopher J. Tignanelli MD | 13 | 14 1 Department of Medicine, Division of General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA 2 Department of Medicine, Division of Endocrinology, University of North Carolina, Chapel Hill, North Carolina, USA 3 Humana Health Services Research Center, Miami University, Miami, Florida, USA 4 UnitedHealth Group Research and Development, Minnetonka, Minnesota, USA 5 Department of Medicine Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA 6 Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA 7 Department of Medicine, Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA 8 Department of Medicine/Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA 9 Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, Texas, USA 10 Department of Medicine, Division of General Internal Medicine, John Hopkins, Baltimore, Maryland, USA 11 Department of Medicine, Weill Cornell Medicine, New York, New York, USA 12 Department of Emergency Medicine, Alameda County, Oakland, California, USA 13 Department of Epidemiology, Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, Minnesota, USA 14 Department of Medicine, Division of Pulmonary Medicine, University of Minnesota, Minneapolis, Minnesota, USA 15 Department of Surgery, Division of Surgical Oncology, University of Minnesota, Minneapolis, Minnesota, USA Correspondence Carolyn T. Bramante, MD, MPH, 420 Delaware St SE, MMC 276, Minneapolis, MN 55455, USA. Email: bramante@umn.edu Abstract Observational studies suggest outpatient metformin use is associated with reduced mortality from coronavirus disease‐2019 (COVID‐19). Metformin is known to decrease interleukin‐6 and tumor‐necrosis factor‐α, which appear to contribute to morbidity in Funding information Agency for Healthcare Research and Quality, Grant/Award Number: K12HS026379; UMN Rapid Response Covid Grant, Grant/Award Number: UM 2020‐2231; COVID‐19. We sought to understand whether outpatient metformin use was associated with reduced odds of severe COVID‐19 disease in a large US healthcare data set. Retrospective cohort analysis of electronic health record (EHR) data that was pooled across This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. © 2021 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC J Med Virol...
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit